Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Depreciation and Depletion (2016 - 2025)

Historic Depreciation and Depletion for Aytu Biopharma (AYTU) over the last 15 years, with Q4 2025 value amounting to $100000.0.

  • Aytu Biopharma's Depreciation and Depletion changed 0.0% to $100000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $300000.0, marking a year-over-year decrease of 4000.0%. This contributed to the annual value of $200000.0 for FY2025, which is 7777.78% down from last year.
  • Aytu Biopharma's Depreciation and Depletion amounted to $100000.0 in Q4 2025, which was down 0.0% from $100000.0 recorded in Q3 2025.
  • Over the past 5 years, Aytu Biopharma's Depreciation and Depletion peaked at $500000.0 during Q2 2021, and registered a low of $100000.0 during Q1 2021.
  • In the last 5 years, Aytu Biopharma's Depreciation and Depletion had a median value of $300000.0 in 2022 and averaged $257894.7.
  • As far as peak fluctuations go, Aytu Biopharma's Depreciation and Depletion skyrocketed by 212222.22% in 2021, and later tumbled by 6666.67% in 2024.
  • Over the past 5 years, Aytu Biopharma's Depreciation and Depletion (Quarter) stood at $400000.0 in 2021, then changed by 0.0% to $400000.0 in 2022, then decreased by 25.0% to $300000.0 in 2023, then tumbled by 66.67% to $100000.0 in 2024, then changed by 0.0% to $100000.0 in 2025.
  • Its Depreciation and Depletion was $100000.0 in Q4 2025, compared to $100000.0 in Q3 2025 and $100000.0 in Q1 2025.